Associated Papers
Integrating evidence from protein domains to identify cancer driver mutations.
Ostroverkhova D et al.
Protein Science : a Publication of the Protein Society, 2026
Targeting driver mutations in lung cancer with interstitial pneumonia: A nationwide study in Japan.
Ikeda S et al.
European Journal of Cancer (oxford, England : 1990), 2026
Tumor evolution and immune microenvironment dynamics in primary and relapsed mantle cell lymphoma.
Wan H et al.
Cell Reports. Medicine, 2025
Deciphering the differential impact of CDK4 mutations on abemaciclib binding in oral squamous cell carcinoma: a precision medicine approach.
Huang Y et al.
Irish Journal of Medical Science, 2025
Germline Non-CDKN2A Variants in Melanoma and Associated Hereditary Cancer Syndromes.
Fiasconaro CA et al.
Diseases (basel, Switzerland), 2025
Reannotation of cancer mutations based on expressed RNA transcripts reveals functional non-coding mutations in melanoma.
Pepe D et al.
American Journal of Human Genetics, 2025
Circulating tumor DNA profiling for non-invasive genomic analysis in Indian lung cancer patients: A real-world experience.
Jha P et al.
The Journal of Liquid Biopsy, 2025
GLI1 confers resistance to PARP inhibitors by activating the DNA damage repair pathway.
Ikeuchi H et al.
Oncogene, 2024
NGS detection of gene rearrangements and METexon14 mutations in liquid biopsy of advanced NSCLC patients: A study of two Italian centers.
Verzè M et al.
The Journal of Liquid Biopsy, 2024
Clinical relevance of somatic mutations in Chinese lung adenocarcinoma and their prognostic implications for survival.
Li T et al.
Cancer Medicine, 2024
Targeted DNA Sequencing of Cutaneous Melanoma Identifies Prognostic and Predictive Alterations.
Haugh AM et al.
Cancers, 2024
Rapid detection of mutations in CSF-cfTNA with the Genexus Integrated Sequencer.
Arjuna S et al.
Journal of Neuro-oncology, 2024
The Utility of NGS Analysis in Homologous Recombination Deficiency Tracking.
Tsantikidi A et al.
Diagnostics (basel, Switzerland), 2023
Standing in the canine precision medicine knowledge gap: Improving annotation of canine cancer genomic biomarkers through systematic comparative analysis of human cancer mutations in COSMIC.
Sakthikumar S et al.
Veterinary and Comparative Oncology, 2023
Molecular Features of Resected Melanoma Brain Metastases, Clinical Outcomes, and Responses to Immunotherapy.
Vasudevan HN et al.
Jama Network Open, 2023
Identification of patient-specific CD4+ and CD8+ T cell neoantigens through HLA-unbiased genetic screens.
Cattaneo CM et al.
Nature Biotechnology, 2023
Noncanonical β-catenin interactions promote leukemia-initiating activity in early T-cell acute lymphoblastic leukemia.
Panelli P et al.
Blood, 2023
Targeting the recurrent Rac1P29S neoepitope in melanoma with heterologous high-affinity T cell receptors.
Immisch L et al.
Frontiers in Immunology, 2023
H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma.
Immisch L et al.
Journal for Immunotherapy of Cancer, 2022
Genomic And Tumor Microenvironment Differences Between Cell Cycle Progression Pathway Altered/Non-Altered Patients With Lung Adenocarcinoma.
Shan G et al.
Frontiers in Oncology, 2022
Rearrangement-mediated cis-regulatory alterations in advanced patient tumors reveal interactions with therapy.
Zhang Y et al.
Cell Reports, 2021
Targeted genomic analysis of 364 adrenocortical carcinomas.
Pozdeyev N et al.
Endocrine-related Cancer, 2021
Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Hescheler DA et al.
Frontiers in Endocrinology, 2021
A risk-associated Active transcriptome phenotype expressed by histologically normal human breast tissue and linked to a pro-tumorigenic adipocyte population.
Kang T et al.
Breast Cancer Research : Bcr, 2020
Genetic Profiling of Advanced Melanoma: Candidate Mutations for Predicting Sensitivity and Resistance to Targeted Therapy.
Olbryt M et al.
Targeted Oncology, 2020
Diversity spectrum analysis identifies mutation-specific effects of cancer driver genes.
Dong X et al.
Communications Biology, 2020
Comprehensive Genomic Profiling of Rare Tumors: Routes to Targeted Therapies.
Wang S et al.
Frontiers in Oncology, 2020
Analysis of error profiles in deep next-generation sequencing data.
Ma X et al.
Genome Biology, 2019
Analysis on GENIE reveals novel recurrent variants that affect molecular diagnosis of sizable number of cancer patients.
Koyama T et al.
Bmc Cancer, 2019
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
A novel germline mutation in CDK4 codon 24 associated to familial melanoma.
Bottillo I et al.
Clinical Genetics, 2018
Comparison of algorithms for the detection of cancer drivers at subgene resolution.
Porta-Pardo E et al.
Nature Methods, 2017
Inherited Disease Genetics Improves the Identification of Cancer-Associated Genes.
Zhao B et al.
Plos Genetics, 2016
Targeting human melanoma neoantigens by T cell receptor gene therapy.
Leisegang M et al.
The Journal of Clinical Investigation, 2016
Functional annotation of rare gene aberration drivers of pancreatic cancer.
Tsang YH et al.
Nature Communications, 2016
Characterization of Somatic Mutations in Air Pollution-Related Lung Cancer.
Yu XJ et al.
Ebiomedicine, 2015
Clonal architectures and driver mutations in metastatic melanomas.
Ding L et al.
Plos One, 2014
Initial genome sequencing and analysis of multiple myeloma.
Chapman MA et al.
Nature, 2011
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas.
Smalley KS et al.
Molecular Cancer Therapeutics, 2008
Genomic Profiling of Aggressive Thyroid Cancer in Association With its Clinicopathological Characteristics.
Kim JH et al.
In Vivo (athens, Greece), 0